Nov 16, 2022 8:30 am EST Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension
Jun 08, 2022 8:00 am EDT Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension
Mar 15, 2022 8:00 am EDT Mineralys Therapeutics Appoints Adam Levy as Chief Financial Officer and Chief Business Officer
